Literature DB >> 24338975

Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.

Padma P Nanaware1, Manoj P Ramteke, Arun K Somavarapu, Prasanna Venkatraman.   

Abstract

Gankyrin, a non-ATPase component of the proteasome and a chaperone of proteasome assembly, is also an oncoprotein. Gankyrin regulates a variety of oncogenic signaling pathways in cancer cells and accelerates degradation of tumor suppressor proteins p53 and Rb. Therefore gankyrin may be a unique hub integrating signaling networks with the degradation pathway. To identify new interactions that may be crucial in consolidating its role as an oncogenic hub, crystal structure of gankyrin-proteasome ATPase complex was used to predict novel interacting partners. EEVD, a four amino acid linear sequence seems a hot spot site at this interface. By searching for EEVD in exposed regions of human proteins in PDB database, we predicted 34 novel interactions. Eight proteins were tested and seven of them were found to interact with gankyrin. Affinity of four interactions is high enough for endogenous detection. Others require gankyrin overexpression in HEK 293 cells or occur endogenously in breast cancer cell line- MDA-MB-435, reflecting lower affinity or presence of a deregulated network. Mutagenesis and peptide inhibition confirm that EEVD is the common hot spot site at these interfaces and therefore a potential polypharmacological drug target. In MDA-MB-231 cells in which the endogenous CLIC1 is silenced, trans-expression of Wt protein (CLIC1_EEVD) and not the hot spot site mutant (CLIC1_AAVA) resulted in significant rescue of the migratory potential. Our approach can be extended to identify novel functionally relevant protein-protein interactions, in expansion of oncogenic networks and in identifying potential therapeutic targets.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  binding; function; hub protein; inhibition; mutation; short linear sequence motif

Mesh:

Substances:

Year:  2014        PMID: 24338975     DOI: 10.1002/prot.24494

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  14 in total

Review 1.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

Review 2.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

3.  Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.

Authors:  Alex M Chapman; Brian R McNaughton
Journal:  ACS Chem Biol       Date:  2015-05-22       Impact factor: 5.100

4.  Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.

Authors:  Dipti Kanabar; Mimansa Goyal; Emma I Kane; Tejashri Chavan; Abbas Kabir; Xuechun Wang; Snehal Shukla; Joseph Almasri; Sona Goswami; Gizem Osman; Marino Kokolis; Donald E Spratt; Vivek Gupta; Aaron Muth
Journal:  J Med Chem       Date:  2022-06-27       Impact factor: 8.039

5.  Protein-Protein Interactions as New Targets for Ion Channel Drug Discovery.

Authors:  Svetla Stoilova-McPhie; Syed Ali; Fernanda Laezza
Journal:  Austin J Pharmacol Ther       Date:  2013-12-31

6.  Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase.

Authors:  Alex M Chapman; Bryce E Rogers; Brian R McNaughton
Journal:  Biochemistry       Date:  2014-10-29       Impact factor: 3.162

7.  Discovery of novel interacting partners of PSMD9, a proteasomal chaperone: Role of an Atypical and versatile PDZ-domain motif interaction and identification of putative functional modules.

Authors:  Nikhil Sangith; Kannan Srinivasaraghavan; Indrajit Sahu; Ankita Desai; Spandana Medipally; Arun Kumar Somavarappu; Chandra Verma; Prasanna Venkatraman
Journal:  FEBS Open Bio       Date:  2014-06-06       Impact factor: 2.693

8.  Peptiderive server: derive peptide inhibitors from protein-protein interactions.

Authors:  Yuval Sedan; Orly Marcu; Sergey Lyskov; Ora Schueler-Furman
Journal:  Nucleic Acids Res       Date:  2016-05-03       Impact factor: 16.971

9.  Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα.

Authors:  Ying Sun; Yu-Jun Tan; Zhan-Zhao Lu; Bing-Bing Li; Cheng-Hong Sun; Tao Li; Li-Li Zhao; Zhong Liu; Gui-Min Zhang; Jing-Chun Yao; Jie Li
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

10.  Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.

Authors:  Anasuya Chattopadhyay; Cornelius J O'Connor; Fengzhi Zhang; Celine Galvagnion; Warren R J D Galloway; Yaw Sing Tan; Jamie E Stokes; Taufiq Rahman; Chandra Verma; David R Spring; Laura S Itzhaki
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.